Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SANDOZ INC via SANDOZ INC
2026 · third_quarter · Q3
Policies related to Medicare coverage and reimbursement of biosimilars Promoting a resilient pharmaceutical supply chain Policies related to serial patent litigation under the Hatch-Waxman Act. Issues related to increasing access to generic and biosimilar medications
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SANDOZ INC via SANDOZ INC
2026 · second_quarter · Q2
Source: Senate LDA
Policies related to the ASP calculation in Medicare Part B Promoting a resilient pharmaceutical supply chain Policies related to serial patent litigation under the Hatch-Waxman Act. Issues related to increasing access to generic and biosimilar medications
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SANDOZ INC via SANDOZ INC
2026 · first_quarter · 1A
Policies related to the ASP calculation in Medicare Part B Promoting a resilient pharmaceutical supply chain Policies related to serial patent litigation under the Hatch-Waxman Act. Issues related to increasing access to generic and biosimilar medications
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SANDOZ INC via SANDOZ INC
2026 · first_quarter · Q1
Policies related to the ASP calculation in Medicare Part B Promoting a resilient pharmaceutical supply chain Policies related to serial patent litigation under the Hatch-Waxman Act. Issues related to increasing access to generic and biosimilar medications
Filing targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SANDOZ INC via SANDOZ INC
2025 · fourth_quarter · Q4
Advocating to remove non-payer discounts from the ASP calculation for Medicare Part B Promoting a resilient pharmaceutical supply chain Advocating to amend Hatch-Waxman to limit brand companies from serially suing generic companies over the same molecule. issues related to generic and biosimilar access
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
SANDOZ INC via SANDOZ INC
2025 · third_quarter · Q3
Advocating to remove non-payer discounts from the ASP calculation for Medicare Part B Promoting a resilient pharmaceutical supply chain Advocating to emaned Hatch-Waxmen to limit brand companies from serially suing generic companies over the same molecule.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, White House Office